ALKERMES, INC.

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.alkermes.com
Clinical Trials
Related News

A Long-Term Safety Study of ALKS 5461

Phase 3
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: ALKS 5461
First Posted Date
2014-05-19
Last Posted Date
2018-12-14
Lead Sponsor
Alkermes, Inc.
Target Recruit Count
1485
Registration Number
NCT02141399
Locations
🇵🇷

Alkermes Investigational Site, San Juan, Puerto Rico

A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)

Phase 3
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: ALKS 5461
First Posted Date
2014-03-12
Last Posted Date
2019-08-14
Lead Sponsor
Alkermes, Inc.
Target Recruit Count
66
Registration Number
NCT02085135
Locations
🇨🇦

Alkermes Investigational Site, Halifax, Nova Scotia, Canada

A Study of ALKS 5461 in Healthy Volunteers

Phase 1
Completed
Conditions
Pharmacokinetics
Interventions
Drug: ALKS 5461
Drug: Placebo
First Posted Date
2014-02-21
Last Posted Date
2014-04-21
Lead Sponsor
Alkermes, Inc.
Target Recruit Count
104
Registration Number
NCT02068105
Locations
🇺🇸

Alkermes Investigational Site, Overland Park, Kansas, United States

A Study of ALKS 3831 in Adults With Schizophrenia

First Posted Date
2013-07-19
Last Posted Date
2021-10-06
Lead Sponsor
Alkermes, Inc.
Target Recruit Count
347
Registration Number
NCT01903837
Locations
🇨🇿

Alkermes Investigational Site, Praha, Czechia

An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)

First Posted Date
2013-07-10
Last Posted Date
2017-08-25
Lead Sponsor
Alkermes, Inc.
Target Recruit Count
291
Registration Number
NCT01895452
Locations
🇺🇦

Roshchino township, Vinnytsia, Ukraine

🇺🇦

Alkermes Investigational Site, Ternopil, Ukraine

A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)

Phase 3
Completed
Conditions
Schizophrenia
Interventions
Drug: ALKS 9072, High
Drug: ALKS 9072, Low
First Posted Date
2012-06-22
Last Posted Date
2018-09-25
Lead Sponsor
Alkermes, Inc.
Target Recruit Count
478
Registration Number
NCT01626456
Locations
🇺🇦

Alkermes Investigational Site, Vinnytsia, Ukraine

A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)

Phase 2
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: ALKS 5461
Drug: Placebo
First Posted Date
2011-12-28
Last Posted Date
2019-05-21
Lead Sponsor
Alkermes, Inc.
Target Recruit Count
142
Registration Number
NCT01500200
Locations
🇺🇸

Alkermes Investigational Site, Bellevue, Washington, United States

A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia

First Posted Date
2011-12-16
Last Posted Date
2018-08-29
Lead Sponsor
Alkermes, Inc.
Target Recruit Count
88
Registration Number
NCT01493726
Locations
🇺🇸

Alkermes Investigational Site, Irving, Texas, United States

A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia

Phase 3
Completed
Conditions
Schizophrenia
Interventions
Drug: ALKS 9072
Drug: Placebo
First Posted Date
2011-11-10
Last Posted Date
2019-01-30
Lead Sponsor
Alkermes, Inc.
Target Recruit Count
623
Registration Number
NCT01469039
Locations
🇺🇦

Alkermes Investigational Site, Vinnytsya, Ukraine

🇺🇸

Alkermes Investigational site, Leesburg, Florida, United States

A Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration

Phase 4
Completed
Conditions
Opioid Dependence
Interventions
Drug: VIVITROL 380mg
First Posted Date
2011-10-17
Last Posted Date
2015-07-13
Lead Sponsor
Alkermes, Inc.
Target Recruit Count
27
Registration Number
NCT01453374
Locations
🇺🇸

Friends Research Institute, Baltimore, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy